KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to 2.63%.

  • Bristol Myers Squibb's EBIT Margin rose 81500.0% to 2.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.78%, marking a year-over-year increase of 258100.0%. This contributed to the annual value of 46.27% for FY2024, which is 412600.0% down from last year.
  • Bristol Myers Squibb's EBIT Margin amounted to 2.63% in Q3 2025, which was up 81500.0% from 13.03% recorded in Q2 2025.
  • Bristol Myers Squibb's 5-year EBIT Margin high stood at 1.8% for Q1 2023, and its period low was 121.77% during Q1 2024.
  • Moreover, its 5-year median value for EBIT Margin was 6.44% (2022), whereas its average is 13.64%.
  • Per our database at Business Quant, Bristol Myers Squibb's EBIT Margin plummeted by -1235700bps in 2024 and then soared by 1212200bps in 2025.
  • Bristol Myers Squibb's EBIT Margin (Quarter) stood at 4.16% in 2021, then crashed by -55bps to 6.44% in 2022, then plummeted by -45bps to 9.33% in 2023, then tumbled by -303bps to 37.57% in 2024, then skyrocketed by 93bps to 2.63% in 2025.
  • Its EBIT Margin stands at 2.63% for Q3 2025, versus 13.03% for Q2 2025 and 0.55% for Q1 2025.